GlassScriptPhysician profile
Brian Marshall Thompson
NPI 1821024993
$10,931.96
in general payments reported to CMS, 2019-2025
60 companies · $47.37 in 2025
The $47.37 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,406 · 2020: $764 · 2021: $1,570 · 2022: $2,850 · 2023: $3,169 · 2024: $125 · 2025: $47.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,163 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,162.50 |
| Education | $179.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,002.19 | 2019-2023 | Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $1,077.98 | 2019-2023 | Nuplazid |
| Abbvie INC. | $901.50 | 2019-2025 | Botox, Qulipta, Ubrelvy |
| Biohaven Pharmaceuticals, INC. | $761.97 | 2021 | |
| Neurocrine Biosciences, INC. | $756.24 | 2022-2023 | Ingrezza, Ongentys |
| Biohaven Pharmaceutical Holding Company LTD. | $749.85 | 2022 | |
| Novartis Pharmaceuticals Corporation | $394.44 | 2019-2022 | |
| Emd Serono, INC. | $299.37 | 2019-2023 | Mavenclad |
| Ucb, INC. | $279.86 | 2019-2023 | Briviact |
| Livanova USA, INC. | $271.68 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Acorda Therapeutics, INC | $182.94 | 2019-2023 | Inbrija |
| Genzyme Corporation | $170.66 | 2019-2020 | |
| Lundbeck LLC | $164.50 | 2019-2020 | |
| Eisai INC. | $164.08 | 2019-2023 | |
| Merz Pharmaceuticals, LLC | $152.64 | 2022-2023 | Xeomin |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.